Biofrontera AG

Notice of first quarterly report of 2017

Business news for the stock market

Leverkusen, Germany (pta019/09.05.2017/10:05) - Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, will be announcing its financial results for the three-month period ended March 31, 2017 on 19 May 2017.

Conference calls for shareholders and interested investors will be held on 19 May 2017 at the following times:

3.00pm CEST (9.00am EDT) conference call in German:
Dial-in number: [phone]
Conference code: 88321813 #

4.00pm CEST (10.00am EDT) conference call in English:
Dial-in number Germany: [phone]
Dial-in number UK: [phone]
Dial-in number USA: [phone]
Dial-in number USA (New York): [phone]
Conference code: 39779540 #

- Ends -

Enquiries, please contact:
Biofrontera AG
Thomas Schaffer, Chief Financial Officer
[phone]
[e-mail]
http://www.biofrontera.com

IR Germany: Brainwell Asset Solutions
Jürgen Benker
[phone]

IR UK: Seton Services
Toni Vallen
[phone]

IR/Media US:
The Ruth Group
Lee Roth (Investors)
[phone]

[e-mail]
Kirsten Thomas (Media)
[phone]
[e-mail]

About Biofrontera
Biofrontera (FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specializing in the development, sale and distribution of drugs, medical devices and medical cosmetics for the care and treatment of skin diseases. Biofrontera's lead product is Ameluz®, a topical prescription drug which is approved and marketed in Europe and the U.S. in combination with its medical lamp BF-RhodoLED® for photodynamic therapy (PDT) treatment of mild and moderate actinic keratosis. Ameluz® is also approved in the EU for the treatment of superficial and nodular basal cell carcinomas. Biofrontera is the first German pharmaceutical start-up company to obtain centralized EU and now U.S. approval for a medical device/drug it has developed itself.
The company also markets the Belixos® dermatological range of cosmetics. Belixos® products contain combinations of active substances extracted from plants, and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All Belixos® products are available in Europe through Amazon.
The Biofrontera Group was established in 1997 by Prof. Dr. Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.
For more information, visit http://www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor & public relations
phone: [phone]
e-mail: [e-mail]
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate

[ source: http://www.pressetext.com/news/20170509019 ]